Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10712959 | 0.85 | — | — | |
| SCHEMBL4947416 | 0.85 | FDPS (0.39) | FDPSBLMTDP1ALOX15TSHR | |
| SCHEMBL12214446 | 0.80 | FDPS (0.50) | FDPSBLMTDP1ALOX15TSHR | |
| SCHEMBL21091889 | 0.74 | FDPS (0.43) | FDPSBLMTDP1 | |
| SCHEMBL21102553 | 0.72 | FDPS (0.41) | FDPSBLMTDP1 | |
| SCHEMBL8998513 | 0.71 | — | — | |
| SCHEMBL21096084 | 0.70 | CA2 (0.30) | — | |
| SCHEMBL10522686 | 0.69 | — | — | |
| SCHEMBL337713 | 0.69 | — | — | |
| SCHEMBL2811015 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219714-A2 | RNA INTERFERENCE MEDIATED INHIBITION OF TMPRSS6 | Silence Therapeutics GmbH (DE) | 2023-08-02 | — | — | EP | disclosed |
| US-20220025377-A1 | PRODUCTS AND COMPOSITIONS | SILENCE THERAPEUTICS GMBH (DE) | 2022-01-27 | — | — | US | disclosed |
| US-11174483-B2 | Products and compositions | SILENCE THERAPEUTICS GMBH (DE) | 2021-11-16 | — | — | US | disclosed |
| EP-3826720-A2 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF TMPRSS6 AND IRON CHELATORS | Silence Therapeutics GmbH (DE) | 2021-06-02 | — | — | EP | disclosed |
| US-20200208158-A1 | PRODUCTS AND COMPOSITIONS | SILENCE THERAPEUTICS GMBH (DE) | 2020-07-02 | — | — | US | disclosed |
| EP-3607068-A1 | PRODUCTS AND COMPOSITIONS | Silence Therapeutics GmbH (DE) | 2020-02-12 | — | — | EP | disclosed |
| WO-2020021108-A2 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF TMPRSS6 AND IRON CHELATORS | SILENCE THERAPEUTICS GMBH (DE) | 2020-01-30 | — | — | WO | disclosed |
| EP-3598995-A1 | PRODUCTS AND COMPOSITIONS | Silence Therapeutics GmbH (DE) | 2020-01-29 | — | — | EP | disclosed |
| WO-2018185240-A1 | PRODUCTS AND COMPOSITIONS | SILENCE THERAPEUTICS GMBH (DE) | 2018-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200208158-A1 | PRODUCTS AND COMPOSITIONS | TMPRSS6, FECH, TFRC | FDPS 211/4885BLM 4006/4885TDP1 542/4885 |
| US-11174483-B2 | Products and compositions | TMPRSS6, FECH, TFRC | FDPS 211/4885BLM 4006/4885TDP1 542/4885 |
| US-20220025377-A1 | PRODUCTS AND COMPOSITIONS | TMPRSS6, FECH, TFRC | FDPS 211/4885BLM 4006/4885TDP1 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.